Clinical trials: Salivary Duct Carcinoma, open to volunteers
Salivary Gland Neoplasm Duct
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma…
- Trial name
- NCT06348264
- Testing
- Rezvilutamide, Leuprolide Acetate
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Peking University First Hospital
Salivary Duct Carcinoma
Phase II Dutasteride in Combination With CAB vs CAB in SDC
Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB) therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients.
- Trial name
- DUCT (NCT05513365)
- Testing
- Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Radboud University Medical Center